Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Inclusion Criteria: 1. HFrEF or HFmrEF, and ICD±CRT therapy \> 3 months 2. at least 10 documented VT episodes (either nsVT (non-sustained ventricular tachycardia) or sVT (sustained ventricular tachycardia) ± ICD (mplantable cardioverter-defibrillator) treatment) within the last 12 months plus: * nt-proBNP \> 500pg/mL or * Left-ventricular Ejection Fraction (LV-EF) \< 35% or * hospitalization for heart failure within the last 12 months or * \> 100 nsVTs within the last 12 months * \> 1 sVT/VF (ventricular function) within the last 12 months 3. Informed consent has to be given in written form. 4. estimated glomerular filtration rate (eGFR) \> 30 ml/min/1.73m2 5. Blood pressure before first drug dosing: blood pressure systolic \> 100 mmHg 6. Blood pressure before first drug dosing: blood pressure diastolic \> 60 mmHg Exclusion Criteria: 1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis 2. Ongoing ventricular arrhythmia 3. Known allergy to SGLT-2 inhibitors 4. Haemodynamic instability as defined by intravenous administration of catecholamine, calciumsensitizers or phosphodiesterase inhibitors 5. \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea 6. Planned catheter ablation for ventricular arrhythmia 7. Planned explantation of ICD, or planned up/downgrade to/from CRT-D device 8. Existing therapy with SGLT-2 inhibitors